Sign in
Taking peoplePhase 2/3

Fractional dose singles vaccination

Key facts

Who runs it
Leids Universitair Medisch Centrum (LUMC)
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 2/3
People taking part
104 people, planned
Started
1 Oct 2026
Expected to end
2 Feb 2027
Type of study
Interventional
Record updated
28 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Aged between 50 and 85 years at the time of informed consent
  • Capable of giving personal signed informed consent, which includes compliance with the requirements listed in this protocol
  • Living in the Netherlands for over 30 years or a history of chickenpox

Who cannot take part

  • Previous vaccination against Herpes Zoster or chickenpox
  • Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation
  • Receipt of any other non-study vaccine within 28 days, before first study dose
  • Anticipated receipt of any other non-study vaccine within 28 days, after last study dose administration
  • Receipt of systemic or topical corticosteroids
  • Women who are pregnant or breastfeeding. A urine pregnancy test will be performed in women under 53 years of age who have menstruated within the previous 12 months
  • History of Herpes Zoster in the last 5 years before inclusion
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
  • Individuals with a history of autoimmune disease or an active autoimmune disease requir-ing therapeutic intervention
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opin-ion of the investigator, contraindicate intramuscular injection
  • A medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participa-tion or, in the investigator#s judgment, make the participant inappropriate for the study
  • Immunosuppressed individuals with known or suspected immunodeficiency, as determined by history

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To determine non-inferiority of the antibody response against VZV four weeks after the vaccination of the intradermal fractional dose compared to the full dose.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
SHING-ID: Fractional dose shingles vaccination
Record updated
28 September 2026